86 related articles for article (PubMed ID: 21272249)
1. Pathological role of aminolevulinate in uremic patients.
Hasuike Y; Nonoguchi H; Tokuyama M; Hata R; Kitamura R; Hori K; Nanami M; Otaki Y; Kuragano T; Nakanishi T
Ther Apher Dial; 2011 Feb; 15(1):28-33. PubMed ID: 21272249
[TBL] [Abstract][Full Text] [Related]
2. 5-Aminolevulinic acid induces iron release from ferritin.
Oteiza PI; Kleinman CG; Demasi M; Bechara EJ
Arch Biochem Biophys; 1995 Jan; 316(1):607-11. PubMed ID: 7840672
[TBL] [Abstract][Full Text] [Related]
3. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
4. Serum ferritin concentration: a reliable guide to iron overload in uremic and hemodialyzed patients.
Aljama P; Ward MK; Pierides AM; Eastham EJ; Ellis HA; Feest TG; Conceicao S; Kerr DN
Clin Nephrol; 1978 Sep; 10(3):101-4. PubMed ID: 699405
[TBL] [Abstract][Full Text] [Related]
5. Oxidative stress and delta-ALA-D activity in chronic renal failure patients.
da Silva AC; Rocha JB; Morsch AL; Zanin RF; Kaizer R; Maldonado PA; Arantes LC; Silva LA; Morsch VM; Schetinger MR
Biomed Pharmacother; 2007; 61(2-3):180-5. PubMed ID: 17383846
[TBL] [Abstract][Full Text] [Related]
6. [Iron balance in hemodialysis in chronic uremia].
Kokot F; Warmuz A
Z Urol Nephrol; 1988 Apr; 81(4):263-8. PubMed ID: 3400353
[TBL] [Abstract][Full Text] [Related]
7. [The iron reserve status in patients on regular dialysis treatment].
Zadrazil J; Papajík T; Scudla V; Jezáková J; Budíková M; Slavícek J
Vnitr Lek; 1991 Apr; 37(4):369-75. PubMed ID: 2053308
[TBL] [Abstract][Full Text] [Related]
8. The plasma retinol levels as pro-oxidant/oxidant agents in haemodialysis patients.
Roehrs M; Valentini J; Bulcão R; Moreira JC; Biesalski H; Limberger RP; Grune T; Garcia SC
Nephrol Dial Transplant; 2009 Jul; 24(7):2212-8. PubMed ID: 19228758
[TBL] [Abstract][Full Text] [Related]
9. The influence of the hemodialysis treatment time under oxidative stress biomarkers in chronic renal failure patients.
Valentini J; Grotto D; Paniz C; Roehrs M; Burg G; Garcia SC
Biomed Pharmacother; 2008; 62(6):378-82. PubMed ID: 18166291
[TBL] [Abstract][Full Text] [Related]
10. Human erythrocyte delta-aminolevulinate dehydratase activity and oxidative stress in hemodialysis patients.
Valentini J; Schmitt GC; Grotto D; Santa Maria LD; Boeira SP; Piva SJ; Brucker N; Bohrer D; Pomblum VJ; Emanuelli T; Garcia SC
Clin Biochem; 2007 Jun; 40(9-10):591-4. PubMed ID: 17462617
[TBL] [Abstract][Full Text] [Related]
11. Use of ascorbate-rich dialysate to attenuate oxidative stress in maintenance hemodialysis patients.
Shi XF; Ding F; Zhu QY; Xue J; Lu FM; Gu Y; Lin ST
Ren Fail; 2005; 27(2):213-9. PubMed ID: 15807188
[TBL] [Abstract][Full Text] [Related]
12. Iron supplementation and oxidative stress in patients with uremia.
Shetty JK; Prakash M
Indian J Physiol Pharmacol; 2007; 51(2):179-82. PubMed ID: 18175664
[TBL] [Abstract][Full Text] [Related]
13. [Serum ferritin in renal insufficiency, hemodialysis and kidney transplantation].
Hofmann V; Descoeudres C; Montandon A; Galeazzi RL; Straub PW
Schweiz Med Wochenschr; 1978 Nov; 108(47):1835-8. PubMed ID: 362527
[TBL] [Abstract][Full Text] [Related]
14. The effect of serum albumin level on iron-induced oxidative stress in chronic renal failure patients.
Sezer MT; Akin H; Demir M; Erturk J; Aydin ZD; Savik E; Tunc N
J Nephrol; 2007; 20(2):196-203. PubMed ID: 17514624
[TBL] [Abstract][Full Text] [Related]
15. Results of improvement in adequacy of intermittent hemodialysis in uremic patients.
Grzegorzewska AE; Banachowicz W; Leander M
Rocz Akad Med Bialymst; 2005; 50():314-8. PubMed ID: 16358991
[TBL] [Abstract][Full Text] [Related]
16. Serum ferritin is a marker of morbidity and mortality in hemodialysis patients.
Kalantar-Zadeh K; Don BR; Rodriguez RA; Humphreys MH
Am J Kidney Dis; 2001 Mar; 37(3):564-72. PubMed ID: 11228181
[TBL] [Abstract][Full Text] [Related]
17. Effect of repeated intravenous iron administration in haemodialysis patients on serum 8-hydroxy-2'-deoxyguanosine levels.
Maruyama Y; Nakayama M; Yoshimura K; Nakano H; Yamamoto H; Yokoyama K; Lindholm B
Nephrol Dial Transplant; 2007 May; 22(5):1407-12. PubMed ID: 17264097
[TBL] [Abstract][Full Text] [Related]
18. Iron-induced oxidative stress in haemodialysis patients: a pilot study on the impact of diabetes.
Van Campenhout A; Van Campenhout C; Lagrou A; Manuel-y-Keenoy B
Biometals; 2008 Apr; 21(2):159-70. PubMed ID: 17585373
[TBL] [Abstract][Full Text] [Related]
19. Effects of hemodialysis, dialyser type and iron infusion on oxidative stress in uremic patients.
Müller C; Eisenbrand G; Gradinger M; Rath T; Albert FW; Vienken J; Singh R; Farmer PB; Stockis JP; Janzowski C
Free Radic Res; 2004 Oct; 38(10):1093-100. PubMed ID: 15512797
[TBL] [Abstract][Full Text] [Related]
20. 8-hydroxy-2'-deoxyguanosine of leukocyte DNA as a marker of oxidative stress in chronic hemodialysis patients.
Tarng DC; Huang TP; Wei YH; Liu TY; Chen HW; Wen Chen T; Yang WC
Am J Kidney Dis; 2000 Nov; 36(5):934-44. PubMed ID: 11054349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
